Novel Hope for Dravet Syndrome: Zorevunersen Shows Potential for Disease Modification

Groundbreaking research published in The New England Journal of Medicine on March 5, 2026, offers a potential turning point in the treatment of Dravet syndrome, a rare and devastating genetic neurological disorder. Data from studies of the investigational drug zorevunersen demonstrate, for the first time, the possibility of modifying the course of this disease, rather than simply managing its symptoms.

Understanding Dravet Syndrome

Dravet syndrome is a severe form of epilepsy that begins in infancy. It is characterized by prolonged, febrile seizures and developmental delays. Children with Dravet syndrome typically experience a plateau in their neurodevelopment around the age of two, and often fall behind their peers in achieving developmental milestones. Currently, there are no approved therapies specifically designed to alter the underlying progression of Dravet syndrome.

Zorevunersen: Targeting the Root Cause

Zorevunersen is an investigational RNA medicine developed by Stoke Therapeutics and Biogen. It works by targeting the underlying genetic cause of Dravet syndrome, aiming to restore protein expression. The published data in The New England Journal of Medicine come from Phase 1/2a studies and ongoing open-label extension (OLE) studies.

Key Findings from the Studies

The studies showed substantial and durable reductions in seizure frequency. Importantly, improvements were likewise observed in measures of cognition and behavior. These positive effects were seen in patients treated with zorevunersen in addition to their standard anti-seizure medications (ASMs). The benefits observed in the Phase 1/2a treatment period continued for up to three additional years in the OLE studies.

What’s Next?

These promising results support the ongoing global Phase 3 EMPEROR study, which will further evaluate the efficacy and safety of zorevunersen in a larger patient population. The publication of these initial findings represents a significant step forward in the search for disease-modifying treatments for Dravet syndrome and offers hope for improved outcomes for individuals and families affected by this challenging condition.

About the Publication

The full publication, titled “Zorevunersen in Children and Adolescents with Dravet Syndrome,” appears in the March 5, 2026, issue of The New England Journal of Medicine.